Where does Teika Pharmaceutical Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Teika Pharmaceutical Co., Ltd. ranks #37,857 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Teika Pharmaceutical Co., Ltd. hold?

Teika Pharmaceutical Co., Ltd. holds 7 US utility patents granted between 2016 and 2025, spanning 10 technology areas.

What is Teika Pharmaceutical Co., Ltd.'s Innovation Score?

Teika Pharmaceutical Co., Ltd. has an Innovation Score of 41.5 out of 100 (top 33% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Teika Pharmaceutical Co., Ltd.'s patent grant rate increasing or decreasing?

Teika Pharmaceutical Co., Ltd.'s recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Teika Pharmaceutical Co., Ltd.'s patents?

Teika Pharmaceutical Co., Ltd.'s patents average 16.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Teika Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Teika Pharmaceutical Co., Ltd.

Q: What technology areas does Teika Pharmaceutical Co., Ltd. focus on?

Teika Pharmaceutical Co., Ltd.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 6 patents. Grants appear in 10 CPC subclasses total.

USPTO PatentsView assignee record - 7 granted patents across 10 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Teika ranks #37,857 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 10 technology areas.

#37,857
of 49,997 US assignees by volume: Top 33%
by Innovation Score (41.5/100): 16.3
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R37857 · Foreign Corporation #37,857 · 7 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 7 grants
LOWER-Q #37,857/49,997
PHOTO-FINISH Technological…
CPC-FOCUS A61K · 10 areas
INNOV-PAR 41.5/100
CLAIMS-RICH 16.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Technological Educational Institute OF Crete (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Teika Pharmaceutical · this assignee

41
3D Lighting… · lowest

7

What this shows Teika's Innovation Score is 41.5/100 (top 33% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Teika's grants concentrate

Teika Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 10 CPC subclasses with 85.7% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2021. By volume, Teika sits between Technological Educational Institute OF Crete and Teloip Inc..

Teika's three-year grant acceleration

Teika Pharmaceutical Co., Ltd. shows 2 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Technological Edu…

7
Technological Uni…

7
Tecnologia Bancar…

7
Tecnoviv

7
Tekelec Global

7
Teleport MED

7
Televic Conference

7
Teloip

7
Teika Pharmaceuti… ◀

7

What this shows Teika holds 7 patents at rank #37,805, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Teika

By rank, the assignees closest to #37,805 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Teika's primary technology class.

Teika's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 33% higher than 67% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Teika Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	28.6%
2021	1	14.3%
2022	1	14.3%
2023	1	14.3%
2025partial year	2	28.6%

Which technologies does Teika Pharmaceutical Co., Ltd. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

C07D - Heterocyclic Compounds 1

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

C07C - Acyclic OR Carbocyclic Compounds 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

C07K - Peptides 1

B29L - Indexing Scheme Associated With Subclass B29c, Relating TO Particular Articles 1

B29C - Shaping OR Joining OF PLASTICS; Shaping OF Material IN A Plastic State, NOT Otherwise Provided FOR; After-treatment OF THE Shaped Products, e.g. Repairing 1

B29K - Indexing Scheme Associated With Subclasses B29b, B29c OR B29d, Relating TO Moulding Materials OR TO Materials FOR ; Moulds, ; Reinforcements, Fillers OR Preformed Parts, e.g. Inserts 1

Top 10 of 10 technology areas

Where it ranks

Overall rank by patents

#37,857

of 49,997 tracked assignees

Innovation Score

41.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Teika Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.

Teika Pharmaceutical Co., Ltd.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 85.7% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #37,857 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Teika Pharmaceutical Co., Ltd. against Technological Educational Institute OF Crete, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.